Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck
- PMID: 17869022
- DOI: 10.1016/j.ijrobp.2007.05.052
Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck
Abstract
Purpose: To report long-term data from a prospective trial of subcutaneous (s.c.) amifostine in patients who received chemoradiotherapy for squamous cell carcinoma of the head and neck (SCCHN).
Methods and materials: Patients >or=18 years of age with previously untreated Stage III/IV SCCHN received fractionated radiotherapy, 1.8-2.0 Gy/day, 5 days per week, to a total dose of 70-72 Gy, plus weekly paclitaxel (40 mg/m2) and carboplatin (100 mg/m2) administered intravenously (i.v.) for 6 weeks. All patients received 500 mg s.c. amifostine 30-60 min before radiotherapy with antihistamine and antiemetic prophylaxis.
Results: Twenty patients were evaluable (median age, 55 years). The incidence of Grade 2 xerostomia was 42% and 29% at 12 and 18 months, respectively; there were no reports of Grade >or=3 xerostomia. Grade >or=3 mucositis occurred in 30% of patients, with median time to resolution of 12.5 weeks (range, 5-17 weeks). Survival estimates at 1 and 2 years were 95% and 71%, respectively. All patients experienced Grade 2 weight loss; 7 patients (35%) experienced Grade <or=2 nausea/vomiting. There were no reports of Grade >/=3 amifostine-related adverse events.
Conclusions: Subcutaneous amifostine was well tolerated by patients receiving chemoradiotherapy for SCCHN, with lower rates of nausea/vomiting than reported in trials with i.v. amifostine. Xerostomia and mucositis rates were similar to those reported in trials with i.v. amifostine.
Similar articles
-
Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.Cancer. 2009 Oct 1;115(19):4514-23. doi: 10.1002/cncr.24525. Cancer. 2009. PMID: 19634161 Clinical Trial.
-
The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).Semin Oncol. 2004 Dec;31(6 Suppl 18):2-7. doi: 10.1053/j.seminoncol.2005.02.001. Semin Oncol. 2004. PMID: 15726515 Clinical Trial.
-
Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):684-91. doi: 10.1016/j.ijrobp.2005.08.005. Epub 2005 Oct 21. Int J Radiat Oncol Biol Phys. 2006. PMID: 16243440 Clinical Trial.
-
Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.Semin Oncol. 2002 Dec;29(6 Suppl 19):61-2. doi: 10.1053/sonc.2002.37349. Semin Oncol. 2002. PMID: 12577247 Review.
-
Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy with carboplatin and paclitaxel followed by optional consolidative chemotherapy: a follow-up study after RTOG 98-01.Semin Oncol. 2004 Dec;31(6 Suppl 18):47-51. doi: 10.1053/j.seminoncol.2004.12.012. Semin Oncol. 2004. PMID: 15726523 Review.
Cited by
-
Effectiveness of combined modality radiotherapy of orthotopic human squamous cell carcinomas in Nu/Nu mice using cetuximab, tirapazamine and MnSOD-plasmid liposome gene therapy.In Vivo. 2010 Jan-Feb;24(1):1-8. In Vivo. 2010. PMID: 20133969 Free PMC article.
-
Long-term outcomes of interventions for radiation-induced xerostomia: A review.World J Clin Oncol. 2019 Jan 10;10(1):1-13. doi: 10.5306/wjco.v10.i1.1. World J Clin Oncol. 2019. PMID: 30627521 Free PMC article. Review.
-
A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact.Support Care Cancer. 2010 Aug;18(8):1061-79. doi: 10.1007/s00520-010-0837-6. Epub 2010 Mar 25. Support Care Cancer. 2010. PMID: 20333412
-
Systematic review of amifostine for the management of oral mucositis in cancer patients.Support Care Cancer. 2013 Jan;21(1):357-64. doi: 10.1007/s00520-012-1613-6. Epub 2012 Oct 3. Support Care Cancer. 2013. PMID: 23052919
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical